Falcão-Júnior João Oscar Almeida, Teixeira-Carvalho Andréa, Cândido Eduardo Batista, Lages Elisa Lopes, Ferreira Freitas G Gustavo, Lamaita Rívia Mara, Freire Bonfim Lívia Paula, Borges Salera Rafael, Traiman P Paulo, da Silva-Filho Agnaldo Lopes
Tumori. 2013 Jul-Aug;99(4):540-4. doi: 10.1177/030089161309900417.
The study was undertaken to investigate CCL2/MCP-1, CCL3/ MIP-1α, CCL4/MIP-1β, CCL5/RANTES and CXCL8/IL-8 women with epithelial ovarian cancer.
Sixteen patients diagnosed with epithelial ovarian cancer and 18 healthy women with no evidence of malign neoplasia (control group) aged from 23 to 89 years (mean ± SEM, 58.7 ± 2.3) were included. The epithelial ovarian cancer patients underwent laparotomy and debulking surgery. Chemokines serum levels were measured by cytometric bead array. Statistical analysis was performed using Mann-Whitney and Kendall's tau. P <0.05 was considered statistically significant for all analyses.
The tumor staging (FIGO) was classified into: I in 4 cases (25%), III in 5 cases (31.3%) and stage IV in 7 cases (43.8%). Sera chemokine dosages of CCL2/MCP-1 and CCL4/MIP-1β were lower in epithelial ovarian cancer patients than in the control group (P = 0.021 and P = 0.030, respectively). No significant difference between groups was observed in the levels of CCL3/MIP-1α, CCL5/RANTES and CXCL8/IL-8. No association between the chemokines analyzed and tumor stage was found. The serum level of CCL4/MIP-1β was correlated with CA-125.
The study of serum levels of CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES and CXCL8/IL-8 chemokines in epithelial ovarian cancer patients identified a down-regulation in CCL2/MCP-1 and CCL4/MIP-1β, which suggests that the two chemokines may play an important role in the pathophysiology of ovarian cancer.
本研究旨在调查上皮性卵巢癌女性患者体内的CCL2/MCP - 1、CCL3/MIP - 1α、CCL4/MIP - 1β、CCL5/RANTES和CXCL8/IL - 8水平。
纳入16例诊断为上皮性卵巢癌的患者和18例年龄在23至89岁（平均±标准误，58.7±2.3）、无恶性肿瘤证据的健康女性（对照组）。上皮性卵巢癌患者接受了剖腹术和肿瘤减灭术。采用细胞计数珠阵列法检测趋化因子血清水平。使用Mann - Whitney检验和Kendall's tau进行统计分析。所有分析中，P <0.05被认为具有统计学意义。
肿瘤分期（国际妇产科联盟[FIGO]）分为：I期4例（25%），III期5例（31.3%），IV期7例（43.8%）。上皮性卵巢癌患者血清中CCL2/MCP - 1和CCL4/MIP - 1β趋化因子剂量低于对照组（分别为P = 0.021和P = 0.030）。CCL3/MIP - 1α、CCL5/RANTES和CXCL8/IL - 8水平在两组间未观察到显著差异。未发现所分析的趋化因子与肿瘤分期之间存在关联。CCL4/MIP - 1β血清水平与CA - 125相关。
对上皮性卵巢癌患者血清中CCL2/MCP - 1、CCL3/MIP - 1α、CCL4/MIP - 1β、CCL5/RANTES和CXCL8/IL - 8趋化因子水平的研究发现CCL2/MCP - 1和CCL4/MIP - 1β下调，这表明这两种趋化因子可能在卵巢癌的病理生理学中起重要作用。
